Shares of Veradermics, Incorporated (NYSE:MANE – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $135.60.
Several research analysts have issued reports on the company. Leerink Partners increased their price target on Veradermics from $75.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, April 22nd. Lifesci Capital assumed coverage on Veradermics in a research report on Tuesday, June 16th. They set an “outperform” rating and a $135.00 target price on the stock. Needham & Company LLC initiated coverage on Veradermics in a report on Tuesday, June 2nd. They issued a “buy” rating and a $136.00 target price on the stock. Wall Street Zen downgraded shares of Veradermics from a “hold” rating to a “sell” rating in a research report on Sunday. Finally, Weiss Ratings began coverage on shares of Veradermics in a research note on Tuesday, May 26th. They set a “sell (d+)” rating for the company.
Get Our Latest Analysis on MANE
Veradermics Trading Down 0.3%
Veradermics (NYSE:MANE – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.76).
About Veradermics
MANE is a global manufacturer and supplier of flavors, fragrances and ingredients for the food, beverage, personal care, household and fine fragrance markets. Headquartered in France, the company develops and produces aromatic solutions that are used by consumer goods companies, food processors, perfumers and formulators seeking sensory impact, taste modulation and olfactory character for their products.
The company’s product portfolio includes savory and sweet flavor systems, beverage concentrates, natural extracts, essential oils, fragrance compounds, cosmetic ingredients and specialty functional solutions such as taste enhancers and odor masking agents.
Featured Stories
- Five stocks we like better than Veradermics
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Receive News & Ratings for Veradermics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradermics and related companies with MarketBeat.com's FREE daily email newsletter.
-PUNDIX.png){kind=small}
